Search PubMed⌕ Search

Biomedical subjects

C B Pratt

Publications and source records attributed to C B Pratt.

258 records · Page 15Linked to original sources
PubMedDate not supplied

Outcome for patients with constitutional 13q chromosomal abnormalities and retinoblastoma.

The outcomes for five patients with retinoblastoma and constitutional chromosomal abnormalities involving the long arm of chromosome 13 are reported. All patients demonstrated developmental delay and mental retardation. Four of these patients are alive 23, 21, 15, and 1 year from diagnosis; one died of pneumonia with septicemia. Each of the four survivors has, with aging, shown hypotonia, mutism, contractures, and inability to function independently.

Abnormalities, Multiple↗
PubMedDate not supplied

Dermatofibrosarcoma protuberans: the pediatric experience at St. Jude Children's Research Hospital.

The clinical characteristics and outcome of children with dermatofibrosarcoma protuberans (DFSP) treated at a single institution over a 34-year period were reviewed. A retrospective chart review identified five children with dermatofibrosarcoma protuberans. The diagnosis was confirmed in all cases by one of the authors. Age; sex; clinical group; tumor invasiveness and size, nodal status, and metastases (TNM stage); therapy; and outcome were retrieved from the medical records of these patients. The median age at diagnosis was 12.5 years. There were four boys, and all tumors arose in the extremities or trunk. All children underwent at least two surgical procedures to achieve negative or surgically microscopic positive margins. In addition, one patient received adjuvant radiotherapy for microscopically positive margins. All patients survive free of disease 1 month to 16.5 years after diagnosis. Dermatofibrosarcoma protuberans is rare among children and adolescents. Recognition of this pathologic entity is important for its proper treatment. Surgical resection (with 3-cm margins) is currently the standard therapy for DFSP.

Adolescent↗
PubMedDate not supplied

Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.

In a phase II trial, cisplatin was given by two randomly assigned dose schedules to 53 children with malignant solid tumors. Both schedules, 30 mg/m2/week and 90 mg/m2 every 3 weeks, were associated with drug-related toxic effects involving the renal, hematopoietic, and neuromuscular systems. Pharmacokinetic studies indicated that the initial serum half-life of total platinum was 27.6 minutes, with a terminal half-life of 44.4 hours. Significant antitumor effect was noted in patients with neuroblastoma and malignant germ cell tumors. Use of cisplatin in combination therapy for patients with these diseases is indicated.

Adolescent↗